EFFICACY OF MYRRH IN THE TREATMENT OF HUMAN SCHISTOSOMIASIS MANSONI

RASHIDA BARAKAT High Institute of Public Health, Department of Tropical Health, Alexandria University, Egypt; Imperial College, Department of Infectious Disease Epidemiology, London, United Kingdom

Search for other papers by RASHIDA BARAKAT in
Current site
Google Scholar
PubMed
Close
,
HALA ELMORSHEDY High Institute of Public Health, Department of Tropical Health, Alexandria University, Egypt; Imperial College, Department of Infectious Disease Epidemiology, London, United Kingdom

Search for other papers by HALA ELMORSHEDY in
Current site
Google Scholar
PubMed
Close
, and
ALAN FENWICK High Institute of Public Health, Department of Tropical Health, Alexandria University, Egypt; Imperial College, Department of Infectious Disease Epidemiology, London, United Kingdom

Search for other papers by ALAN FENWICK in
Current site
Google Scholar
PubMed
Close
Restricted access

Myrrh (Mirazid) has been produced and marketed as an antischistosomal drug since 2001. The current study was designed to assess the efficacy of a commercially available product of myrrh. One hundred four individuals, infected with Schistosoma mansoni, were randomized in two groups, one for myrrh and the second for praziquantel. Treatment—whether myrrh or praziquantel—was given twice with a 3-week interval. The cure rate with myrrh was very low, 15.6% after the first treatment, and 8.9% after the second treatment. Egg reduction among uncured persons was also very low, being 17.2% after the first treatment, and 28% after the second treatment. Praziquantel cure rate was 73.7% and 76.3%, and individuals still passing S. mansoni ova after praziquantel treatment showed a substantial reduction in the geometric mean egg counts (84% and 88.2% after the first and second treatments, respectively). When 34 individuals—uncured after two myrrh treatments—were offered praziquantel in the standard dose, 32 of them stopped passing S. mansoni eggs when tested 4 weeks post-treatment. The results of the current study raise serious doubts about the antischistosomal properties of Mirazid.

Author Notes

  • 1

    Hall BL, Oser BL, 1965. Progress in the consideration of flavoring ingredients under the food additive amendment. 3.GRAF substances. Food Technol 19 :151–197.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    Ford RA, Api AM, Letizia CS, 1992. Monographs on fragrance to raw materials. Food Chem Toxicol 30 (Suppl):91s–92s.

  • 3

    Massoud A, Salama O, Bennett JL, 1998. Therapeutic efficacy of new antischistosomal drug, derived from myrrh, in active intestinal schistosomiasis complicated with hepatosplenomegaly. Proceedings of the 9th International Congress of Parasitology (ICOPA IX), Chiba, Japan. Bologna: Monduzzi Editore, Tada I, Kojima S, Tsuji M, eds., 619–623.

    • PubMed
    • Export Citation
  • 4

    Badria F, Abou-Mohamed G, El-Mowafy A, Masoud A, Salama O, 2001. Mirazid: a new schistosomicidal drug. Pharm Biol 39 :127–131.

  • 5

    Botros S, William S, Ebeid F, Cioli D, Katz N, Day T, Bennett J, 2004. Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am J Trop Med Hyg 71 :206–210.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6

    Sheir Z, Nasr A, Massoud A, Salama O, Badra GA, El-Shennawy H, Hassan N, Hammad S, 2001. A safe and effective, herbal antischistosomal therapy derived from myrrh. Am J Trop Med Hyg 65 :700–704.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    El Baz MA, Morsy TA, El Bandary MM, Motawea SM, 2003. Clinical and parasitological studies on the efficacy of Mirazid in treatment of schistosomiasis haematobium in Tatoon, Etsa Center, El Fayoum Governorate. J Egypt Soc Parasitol 33 :761–767.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8

    Katz N, Pellegrino J, 1972. A simple device for quantitative stool thick smear technique in schistosomiasis mansoni. Rev Inst Med Trop São Paulo 14 :397–400.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Gryseels B, Stelma FF, Talla I, Van Dam GJ, Polman K, Sow S, Diaw M, Sturrock RF, Doehring-Schwerdtfeger E, Kardorff R, Decam C, Niag M, Deelder AM, 1994. Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal. Trop Geogr Med 46 :209–219.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Jordan B, Webbe G, 1982. Epidemiology. Jordan P, Webbe G, eds. Schistosomiasis, Epidemiology, Treatment and Control. London: William Heinmann Medical Books, 110–111.

    • PubMed
    • Export Citation
  • 11

    Utzinger J, N’Goran EK, N’Dri A, Lengeler C, Tanner M, 2000. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health 5 :771–778.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12

    Raso G, N’Goran EK, Toty A, Lugenbuhl A, Adjoua CA, Tian-Bi NT, Bogoch II, Vounatsou P, Tanner M, Utzinger J, 2004. Efficacy and side effects of praziquantel against Schistosoma mansoni, a community of western Cote d’Ivoire. Trans R Soc Trop Med Hyg 98 :1–27.

    • PubMed
    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 502 433 44
Full Text Views 315 6 4
PDF Downloads 132 6 4
 

 

 

 
 
Affiliate Membership Banner
 
 
Research for Health Information Banner
 
 
CLOCKSS
 
 
 
Society Publishers Coalition Banner
Save